Viking Therapeutics Inc
VKTXHealthcare|Biotechnology|USA
$38.86
-2.28 (-5.54%)
Tangible Book
$4.33
About
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Stock Price
+24.2%(1Y)
Pipeline Summary
9 total trials2
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
Active: 2Completed: 7
Active Trials (2)
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383Weight Loss
Phase 3Active
Enrollment: 1,100 participants
VK2735 for Weight Management Phase 3
NCT07104500Weight Loss
Phase 3Active
Enrollment: 4,500 participants
BioScore
5.7/10
Watchlist
Ownership
Recent Insider Trades
Aubuchon Neil WilliamBUY
2026-03-104,475 shares @ $33.5
ZANTE GREGSELL
2026-01-0557,661 shares @ $32.9
Mancini MariannaSELL
2026-01-0557,661 shares @ $32.98
Lian BrianSELL
2026-01-05233,409 shares @ $32.96
FOEHR MATTHEW WSELL
2026-01-0216,000 shares @ $35.11
Recent News
2026-06-24 15:31:02
2026-06-24 12:00:05
2026-06-24 11:29:54
Data last updated: Jul 12, 2026, 07:32 PM